SCHEMBL230330

SCHEMBL230330

CCCn1cnc2ccccc21

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.78
LMNA P02545 9/20 0.64
SMN1; SMN2 Q16637 8/20 0.64
HTT P42858 6/20 0.64
EGLN3 Q9H6Z9 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP11B1 P15538 4/20 0.58
CYP11B2 P19099 4/20 0.58
TNF P01375 1/20 0.58
TSHR P16473 3/20 0.57
NPSR1 Q6W5P4 2/20 0.57
PKM P14618 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPT P10636 1/20 0.55
STAT3 P40763 1/20 0.55
GAA P10253 1/20 0.54
RAB9A P51151 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10912945 0.98 TDP1 (0.75) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL180261 0.89 TDP1 (0.72) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL6442808 0.88 TDP1 (1.00) TDP1LMNASMN1; SMN2HTTEGLN3
Hydrochloric Acid SCHEMBL28203320 0.87 TDP1 (0.70) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL327149 0.87 TDP1 (0.70) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL6321085 0.86 TDP1 (0.68) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL4888041 0.86 TDP1 (0.68) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL9853336 0.86 TDP1 (0.68) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL9038701 0.86 TDP1 (0.68) TDP1LMNASMN1; SMN2HTTEGLN3
SCHEMBL3868979 0.86 TDP1 (0.68) TDP1LMNASMN1; SMN2HTTEGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606290-B Method for efficiently catalyzing and synthesizing fluorine-containing polypeptide condensing agent by adopting green acid binding agent 浙江大学 2024-11-01 CN claimed
CN-116606290-A Method for efficiently catalyzing and synthesizing fluorine-containing polypeptide condensing agent by adopting green acid binding agent 浙江大学 2023-08-18 CN claimed
EP-1984968-B1 IONIC LIQUID ELECTROLYTE ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2017-04-05 EP claimed
EP-1404321-A1 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES Schering Aktiengesellschaft (DE) 2004-04-07 EP claimed
WO-2003004023-A1 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-16 WO claimed
US-20260015339-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY UNIVERSITE GRENOBLE ALPES (FR) 2026-01-15 US disclosed
EP-4655285-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY Université Grenoble Alpes (FR) 2025-12-03 EP disclosed
CN-113424016-B Method for obtaining information on an organic solderability preservative on a printed circuit board 德国艾托特克公司 2025-04-15 CN disclosed
CN-116606290-B Method for efficiently catalyzing and synthesizing fluorine-containing polypeptide condensing agent by adopting green acid binding agent 浙江大学 2024-11-01 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
WO-2024156819-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY UNIVERSITE GRENOBLE ALPES (FR) 2024-08-02 WO disclosed
EP-0511187-B1 Process for the preparation of 1H-benzimidazoles UCB SA (BE) 1996-11-20 EP disclosed
EP-0511187-A1 Process for the preparation of 1H-benzimidazoles U C B, S.A. (BE) 1992-10-28 EP disclosed
EP-0428383-A1 Process for surface treatment of copper and copper alloy SHIKOKU CHEMICALS CORPORATION (JP) 1991-05-22 EP disclosed
US-5015473-A Beta-lactamase inhibitors PFIZER INC. (US) 1991-05-14 US disclosed
US-4826833-A ANTIBIOTICS PFIZER INC. (US) 1989-05-02 US disclosed
US-4620871-A SALTS OF PHTHALAZINES AND BENZIMIDAZOLES ESZAKMAGYARORSZAGIVEGYIMUVEK (HU) 1986-11-04 US disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed
US-4151280-A ANTIALLERGENS ROUSSEL UCLAF (FR) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015339-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY CBR1, CYP4X1, CBR3 TDP1 2304/4885LMNA 2391/4885SMN1; SMN2 2691/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK TDP1 959/4885LMNA 4345/4885SMN1; SMN2 2823/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK TDP1 959/4885LMNA 4345/4885SMN1; SMN2 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.